Department of Pharmacology and Toxicology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran.
Department of Pediatrics, Faculty of Medicine, Motahari Hospital, Urmia University of Medical Sciences, Urmia, Iran.
Drug Res (Stuttg). 2021 Mar;71(3):166-170. doi: 10.1055/a-1296-7935. Epub 2020 Nov 11.
A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19.
2019 年末，新型冠状病毒（SARS-CoV-2）引发的 2019 冠状病毒病（COVID-19）疫情在中国武汉暴发，随后迅速在全球蔓延。然而，目前针对 COVID-19 尚无特效抗病毒疗法，使用已批准或正在开发用于其他病毒感染的药物是寻找这种新型病毒感染治疗方法的最快途径之一。法匹拉韦是一种有效的核苷酸类似物药物，可选择性抑制病毒 RNA 依赖性 RNA 聚合酶，或在掺入病毒 RNA 时导致致命的诱变。鉴于最近关于法匹拉韦的研究和讨论，在这篇迷你综述中，我们旨在总结研究法匹拉韦治疗 COVID-19 患者的疗效和安全性的临床试验。
